RxDoctor Payments Data

Gary Bean, MD

Family Medicine · Raleigh, NCNPI 1760452312

Payments from drug & device makers

$8,120in general payments, 2019–2025

Across 466 payments — averaging $17.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$917
  • Lilly USA, LLC$835
  • Boehringer Ingelheim$662
  • Chugai Pharmaceutical Co., Ltd.$500
  • AstraZeneca$424
  • plus $4K from 41 others

What the payments were for

  • Consulting fees$1,10814%
  • Food & beverage$7,00086%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,120 in reported general payments places this provider in the 90th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$73,171
Medicare patients
211
Services billed
1,348

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin65$73,159
MounjaroTirzepatide48$51,933
OzempicSemaglutide48$48,726
EliquisApixaban30$37,420
ArexvyRsvpref3 Antigen/As01e/Pf87$26,990
JanuviaSitagliptin Phosphate20$22,440
Tresiba Flextouch U-200Insulin Degludec14$11,879
XareltoRivaroxaban17$11,037
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$10,338
SymbicortBudesonide/Formoterol Fumarate16$6,392
SynthroidLevothyroxine Sodium50$5,781
ZanaflexTizanidine Hcl13$3,848
Gabapentin114$3,645
Atorvastatin Calcium274$3,067
Rosuvastatin Calcium204$2,579

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$662$73,15965 claims
Lilly USA, LLCMounjaro$835$51,93348 claims
Novo NordiskOzempic$1,002$48,72648 claims
PfizerEliquis$379$37,42030 claims
GSKArexvy$300$26,99087 claims
MerckJanuvia$112$22,44020 claims
Johnson & JohnsonXarelto$365$11,03717 claims
AstraZenecaSymbicort$424$6,39216 claims
AbbVieSynthroid$917$5,78150 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$31$2,513182 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →